Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
$MRNA
Moderna has become the ultimate high-stakes comeback story. The stock has collapsed from its pandemic glory days of $165 all the way down to $47.23, a valuation that effectively prices this mRNA pioneer for failure. Yet the same platform that delivered a vaccine to the world is now targeting something far more valuable: a personalized cancer vaccine. The pipeline is live, the trials are enrolling, and the FDA calendar is filling up.
🔹 The pivot is aggressive and unambiguous. COVID-19 vaccine revenue has largely evaporated, but Moderna has redirected its entire mRNA machinery toward oncology and respiratory combination vaccines. The Merck-partnered melanoma immunotherapy program is the flagship—a personalized cancer vaccine designed to train the immune system to recognize and destroy each patient's unique tumor mutations. Positive Phase II data has already accelerated the program into pivotal trials, and the outcome will define whether this stock is a bargain or a value trap.
🔹 The cash burn narrative is well understood, and that is precisely what creates the asymmetry. The company holds a significant cash reserve and is investing heavily in R&D, with multiple readouts expected over the next 12 to 18 months. The market has punished the spending, but the same spending is what funds the potential breakthroughs. The risk is visible, quantified, and already reflected in the $18.4 billion market cap. What is not yet priced in is the possibility of a single positive FDA approval reshaping the entire revenue trajectory.
🔹 The pipeline depth extends beyond melanoma. A triple-combination respiratory vaccine targeting flu, RSV, and COVID in a single shot is advancing through late-stage trials. If successful, it transforms an annual immunization market into a consolidated, high-efficacy mRNA platform play. The addressable market for cancer vaccines alone is projected to reach tens of billions annually within the next decade, and Moderna is positioned at the front of that race.
🔹 The technical and strategic setup is a classic biotech asymmetry. The stock is trading near its 52-week low, meaning the downside is increasingly limited while the upside from any positive clinical catalyst is exponential. The market has priced in the cash burn and the revenue drought. It has not priced in the possibility that mRNA technology succeeds in oncology. When binary events cluster around a depressed stock, the risk-reward equation tilts sharply.
A platform that saved millions during a pandemic is now hunting a cure for cancer at a $47 price tag. The cash is burning, the trials are running, and the market is watching with skepticism. That combination—deep pessimism and a pipeline full of potential—is exactly where asymmetric returns are born. Are you willing to bet on the science before the headlines confirm it, or does the cash burn keep you on the sidelines?
#TradFi交易分享挑战
⚠️ Not financial advice.
👉 DYOR ‼️
$971 Chip. $47 Cure.
The chasm between legacy and innovation has never been wider on American exchanges. As May 2026 closes, we are witnessing a brutal divergence: artificial intelligence infrastructure is minting trillion-dollar monarchs, while biotech pioneers scrape the bargain bin. The market is ruthlessly voting for the picks-and-shovels of the A.I. gold rush, and the story is told in the cold, hard prices of these five giants.
🔹 $MU — The Memory Monarch Takes the Crown
Micron crossed the $1 trillion market cap threshold for the first time this week, a historic moment that has analysts scrambling to catch up. The stock is now at $971.00 after smashing earnings estimates by over 40%. The secret? The entire 2026 supply of high-bandwidth memory is sold out. Analysts at MarketWise are now whispering about a $2,500 long-term target, arguing that this is no longer a cyclical stock but a structural A.I. utility.
🔹 #TSM — The Geopolitical Tollbooth
Taiwan Semiconductor sits at $418.45, up a staggering 117% year-over-year and hugging its all-time highs. Owning 72% of the global foundry market, TSMC just raised 3nm prices by 15% and cranked its CapEx to the top of its $56 billion range. You can't build A.I. without chips, and you can't build cutting-edge chips without TSMC. That is not a narrative; it is a geographical monopoly.
🔹 $JNJ — The Quiet Fortress
At $225.46, Johnson & Johnson is doing what defensive giants do: surviving. With a 2.18% dividend yield and a 12% year-to-date rise, it is the adult in the room. While facing the Stelara patent cliff, the MedTech and oncology pipelines are plugging the holes, making this a favorite for those seeking shelter from the tech sector's manic swings.
🔹 $MMM — The Legal Anchor
3M is stuck in the mud at $153.13, weighed down by the PFAS "forever chemicals" legacy in Australia. Despite operational improvements, the stock is down from its February high of $173. Analysts call it a "Hold" with an average target of $172.20, but until the legal fog clears, this is a yield play handcuffed by the past.
🔹 $MRNA — The Pipeline Roulette
Moderna has collapsed to $47.23, a painful fall for the pandemic darling. The COVID cash cow is gone, and the pivot to cancer vaccines and RSV combinations is an expensive bet. The short-term charts are weak. The long-term fate rests entirely on FDA clinical results. This is a high-risk biotech lottery ticket at a deep discount.
The gulf between A.I. hardware and struggling biotech is the defining feature of this market. Micron sells shovels; Moderna searches for miracles. Right now, the crowd is sprinting toward the hardware that builds the future while cautiously watching the science that heals it.
How are you positioning in this extreme divergence—doubling down on the A.I. infrastructure boom, or quietly accumulating the beaten-down innovators waiting for their clinical breakthrough?
⚠️ Not financial advice.